X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare with Natco Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs NATCO PHARMA - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES NATCO PHARMA ALKEM LABORATORIES/
NATCO PHARMA
 
P/E (TTM) x - 11.9 - View Chart
P/BV x 6.1 3.2 192.5% View Chart
Dividend Yield % 0.7 1.4 50.5%  

Financials

 ALKEM LABORATORIES   NATCO PHARMA
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-16
NATCO PHARMA
Mar-18
ALKEM LABORATORIES/
NATCO PHARMA
5-Yr Chart
Click to enlarge
High Rs1,5891,080 147.1%   
Low Rs1,232671 183.5%   
Sales per share (Unadj.) Rs417.5592.1 70.5%  
Earnings per share (Unadj.) Rs56.3188.4 29.9%  
Cash flow per share (Unadj.) Rs64.7206.3 31.4%  
Dividends per share (Unadj.) Rs12.708.25 153.9%  
Dividend yield (eoy) %0.90.9 95.6%  
Book value per share (Unadj.) Rs292.9833.6 35.1%  
Shares outstanding (eoy) m119.5736.90 324.0%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x3.41.5 228.5%   
Avg P/E ratio x25.14.6 539.1%  
P/CF ratio (eoy) x21.84.2 513.7%  
Price / Book Value ratio x4.81.1 458.4%  
Dividend payout %22.64.4 515.2%   
Avg Mkt Cap Rs m168,65332,311 522.0%   
No. of employees `000NA4.8 0.0%   
Total wages/salary Rs m9,1713,256 281.7%   
Avg. sales/employee Rs ThNM4,522.5-  
Avg. wages/employee Rs ThNM674.0-  
Avg. net profit/employee Rs ThNM1,439.0-  
INCOME DATA
Net Sales Rs m49,91521,848 228.5%  
Other income Rs m1,645404 407.2%   
Total revenues Rs m51,56122,252 231.7%   
Gross profit Rs m8,4829,284 91.4%  
Depreciation Rs m1,006662 151.9%   
Interest Rs m671154 435.5%   
Profit before tax Rs m8,4518,872 95.3%   
Minority Interest Rs m-1140-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,6061,920 83.6%   
Profit after tax Rs m6,7316,952 96.8%  
Gross profit margin %17.042.5 40.0%  
Effective tax rate %19.021.6 87.8%   
Net profit margin %13.531.8 42.4%  
BALANCE SHEET DATA
Current assets Rs m27,06221,307 127.0%   
Current liabilities Rs m15,3245,920 258.8%   
Net working cap to sales %23.570.4 33.4%  
Current ratio x1.83.6 49.1%  
Inventory Days Days6773 90.8%  
Debtors Days Days41107 38.8%  
Net fixed assets Rs m12,61014,986 84.1%   
Share capital Rs m239369 64.8%   
"Free" reserves Rs m34,49030,353 113.6%   
Net worth Rs m35,02730,760 113.9%   
Long term debt Rs m1,2120-   
Total assets Rs m54,38737,151 146.4%  
Interest coverage x13.658.6 23.2%   
Debt to equity ratio x00-  
Sales to assets ratio x0.90.6 156.1%   
Return on assets %13.619.1 71.2%  
Return on equity %19.222.6 85.0%  
Return on capital %24.929.3 84.7%  
Exports to sales %12.90-   
Imports to sales %3.10-   
Exports (fob) Rs m6,461NA-   
Imports (cif) Rs m1,540NA-   
Fx inflow Rs m6,56310,322 63.6%   
Fx outflow Rs m3,0122,978 101.1%   
Net fx Rs m3,5527,343 48.4%   
CASH FLOW
From Operations Rs m7,2594,636 156.6%  
From Investments Rs m1,864-11,155 -16.7%  
From Financial Activity Rs m-9,2736,509 -142.5%  
Net Cashflow Rs m-150-18 833.3%  

Share Holding

Indian Promoters % 66.9 52.0 128.6%  
Foreign collaborators % 0.0 1.5 -  
Indian inst/Mut Fund % 33.1 7.8 422.2%  
FIIs % 0.0 16.6 -  
ADR/GDR % 0.0 0.0 -  
Free float % 0.0 26.0 -  
Shareholders   68,381 25,395 269.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   FDC LTD.  UNICHEM LAB  DR. REDDYS LAB  ELDER PHARMA  ALEMBIC LTD  

Compare ALKEM LABORATORIES With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Recapitalisation Package for PSBs: The Pros & Cons(Podcast)

Corporate governance issues with certain companies, uncertainty surrounding national elections and global issues like trade wars, Brexit, have taken a toll on the Indian markets.

Related Views on News

NATCO PHARMA Announces Quarterly Results (3QFY19); Net Profit Down 26.7% (Quarterly Result Update)

Feb 14, 2019 | Updated on Feb 14, 2019

For the quarter ended December 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (down 26.7% YoY). Sales on the other hand came in at Rs 6 bn (down 1.0% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

NATCO PHARMA Announces Quarterly Results (2QFY19); Net Profit Up 115.2% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (up 115.2% YoY). Sales on the other hand came in at Rs 5 bn (up 27.4% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

NATCO PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 93.3% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (up 93.3% YoY). Sales on the other hand came in at Rs 5 bn (up 21.0% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

NATCO PHARMA Announces Quarterly Results (4QFY18); Net Profit Up 69.6% (Quarterly Result Update)

May 25, 2018 | Updated on May 25, 2018

For the quarter ended March 2018, NATCO PHARMA has posted a net profit of Rs 3 bn (up 69.6% YoY). Sales on the other hand came in at Rs 8 bn (up 32.9% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

The One Real Estate Stock to Buy Now(The 5 Minute Wrapup)

Feb 13, 2019

The real estate sector is ready to make a comeback. This is the stock to consider buying.

Don't Be Afraid of the Market; Buy Stocks Like This One(The 5 Minute Wrapup)

Feb 14, 2019

During this tough period in the market, a contrarian approach holds huge potential upside for this Smart Money Secrets stock.

Small Caps Under Seige: Could This Be A Once-in-a-Decade Wealth Creating Opportunity?(Profit Hunter)

Feb 14, 2019

Don't let the dark clouds hovering over small caps scare you into hiding; it will rain gold as sentiments recover. Indeed, there is a blood bath. And if you are a first time investor, the correction is deep enough to scare you out of markets.

The 4-Point Plan to Accelerate India to a 10 Trillion Dollar Economy(The 5 Minute Wrapup)

Feb 12, 2019

Two questions I have been eagerly waiting to ask you ever since Budget 2019 was announced.

The Train to 'Small-Cap-Profits Land' is Back on the Station!(Profit Hunter)

Feb 15, 2019

Why its great news that prices for small caps over the last few days have been falling like there's no tomorrow.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Feb 22, 2019 (Close)

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES 5-YR ANALYSIS

COMPARE ALKEM LABORATORIES WITH

MARKET STATS